[
    {
        "id": 9593,
        "drug_name": "Benlysta (Belimumab)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Pediatric Lupus Nephritis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-07-27",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/GSK\/news\/87344",
        "note": "Approved July 27, 2022.",
        "company_entity_id": 379,
        "company_ticker": "GSK",
        "company_name": "GSK plc American Depositary Shares (Each representing two)",
        "company_price": "43.2700",
        "company_change": 0.35,
        "company_percent_change": 0.82,
        "company_optionable": 1,
        "company_number_of_shares": 2058516719,
        "price_change_sparkline": [
            [
                39.0637603938206,
                1706677200
            ],
            [
                40.2424083367376,
                1706763600
            ],
            [
                40.3315497777986,
                1706850000
            ],
            [
                41.1734411655964,
                1707109200
            ],
            [
                41.3517240477183,
                1707195600
            ],
            [
                41.6191483709012,
                1707282000
            ],
            [
                41.4210562796546,
                1707368400
            ],
            [
                41.5101977207156,
                1707454800
            ],
            [
                40.67821093748,
                1707714000
            ],
            [
                40.9951582834745,
                1707800400
            ],
            [
                41.40124707053,
                1707886800
            ],
            [
                41.371533256843,
                1707973200
            ],
            [
                41.5399115344025,
                1708059600
            ],
            [
                41.6191483709012,
                1708405200
            ],
            [
                41.5399115344025,
                1708491600
            ],
            [
                42.16,
                1708578000
            ],
            [
                42.22,
                1708664400
            ],
            [
                42.34,
                1708923600
            ],
            [
                42.38,
                1709010000
            ],
            [
                42.34,
                1709096400
            ],
            [
                41.9,
                1709182800
            ],
            [
                42.03,
                1709269200
            ],
            [
                42.44,
                1709528400
            ],
            [
                42.6,
                1709614800
            ],
            [
                42.62,
                1709701200
            ],
            [
                43.58,
                1709787600
            ],
            [
                43.14,
                1709874000
            ],
            [
                42.92,
                1710129600
            ],
            [
                43.27,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9861,
        "drug_name": "STELARA (ustekinumab)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Psoriatic Arthritis in Pediatric Patients",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-08-01",
        "link": "https:\/\/www.jnj.com\/stelara-ustekinumab-approved-by-the-u-s-food-and-drug-administration-to-treat-pediatric-patients-with-active-psoriatic-arthritis",
        "note": "Approved August 1, 2022.",
        "company_entity_id": 380,
        "company_ticker": "JNJ",
        "company_name": "Johnson & Johnson",
        "company_price": "162.7400",
        "company_change": 1.51,
        "company_percent_change": 0.94,
        "company_optionable": 1,
        "company_number_of_shares": 2408767228,
        "price_change_sparkline": [
            [
                157.701248890579,
                1706677200
            ],
            [
                157.165322682896,
                1706763600
            ],
            [
                155.428524787625,
                1706850000
            ],
            [
                154.6246354761,
                1707109200
            ],
            [
                156.867585900849,
                1707195600
            ],
            [
                156.788189425637,
                1707282000
            ],
            [
                155.220109040193,
                1707368400
            ],
            [
                155.577393178648,
                1707454800
            ],
            [
                156.659170153417,
                1707714000
            ],
            [
                155.289580956004,
                1707800400
            ],
            [
                154.565088119691,
                1707886800
            ],
            [
                156.728642069228,
                1707973200
            ],
            [
                156.55,
                1708059600
            ],
            [
                157.86,
                1708405200
            ],
            [
                158.68,
                1708491600
            ],
            [
                160.45,
                1708578000
            ],
            [
                161.84,
                1708664400
            ],
            [
                160.79,
                1708923600
            ],
            [
                160.98,
                1709010000
            ],
            [
                161.55,
                1709096400
            ],
            [
                161.38,
                1709182800
            ],
            [
                162.12,
                1709269200
            ],
            [
                159.84,
                1709528400
            ],
            [
                159.97,
                1709614800
            ],
            [
                159.34,
                1709701200
            ],
            [
                158.87,
                1709787600
            ],
            [
                159.52,
                1709874000
            ],
            [
                161.23,
                1710129600
            ],
            [
                162.74,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6192,
        "drug_name": "CIMERLI (ranibizumab-ranq) - (Lucentis Biosimilar)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Wet age-related macular degeneration (wAMD), among others",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-08-02",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/CHRS\/news\/88175",
        "note": "Biosimilar approved August 2, 2022.",
        "company_entity_id": 89,
        "company_ticker": "CHRS",
        "company_name": "Coherus BioSciences Inc.",
        "company_price": "2.2400",
        "company_change": -0.030000000000000027,
        "company_percent_change": -1.3199999999999998,
        "company_optionable": 1,
        "company_number_of_shares": 111364152,
        "price_change_sparkline": [
            [
                2.15,
                1706677200
            ],
            [
                2.09,
                1706763600
            ],
            [
                2.06,
                1706850000
            ],
            [
                2.02,
                1707109200
            ],
            [
                2.32,
                1707195600
            ],
            [
                2.32,
                1707282000
            ],
            [
                2.38,
                1707368400
            ],
            [
                2.62,
                1707454800
            ],
            [
                2.82,
                1707714000
            ],
            [
                2.56,
                1707800400
            ],
            [
                2.72,
                1707886800
            ],
            [
                2.85,
                1707973200
            ],
            [
                2.76,
                1708059600
            ],
            [
                2.59,
                1708405200
            ],
            [
                2.48,
                1708491600
            ],
            [
                2.47,
                1708578000
            ],
            [
                2.58,
                1708664400
            ],
            [
                2.5,
                1708923600
            ],
            [
                2.62,
                1709010000
            ],
            [
                2.36,
                1709096400
            ],
            [
                2.28,
                1709182800
            ],
            [
                2.41,
                1709269200
            ],
            [
                2.27,
                1709528400
            ],
            [
                2.18,
                1709614800
            ],
            [
                2.21,
                1709701200
            ],
            [
                2.21,
                1709787600
            ],
            [
                2.39,
                1709874000
            ],
            [
                2.27,
                1710129600
            ],
            [
                2.24,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9624,
        "drug_name": "JUV\u00c9DERM VOLUX XC",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Jawline definition",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-08-03",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/ABBV\/news\/88288",
        "note": "Approved August 3, 2022.",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7156,
        "drug_name": "CALQUENCE (acalabrutinib)",
        "clinical_trial_id": "NCT02477696",
        "has_trial_insight_page": 1,
        "indication": "Chronic Lymphocytic Leukemia (CLL), small lymphocytic lymphoma (SLL) and refractory mantle cell lymphoma (MCL)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-08-05",
        "link": "https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/calquence-tablet-formulation-approved-in-the-us-across-current-indications.html",
        "note": "Approved August 5, 2022.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5685,
        "drug_name": "ENHERTU (trastuzumab deruxtecan)",
        "clinical_trial_id": "NCT03734029",
        "has_trial_insight_page": 1,
        "indication": "HER low breast cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-08-05",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/AZN\/news\/88856",
        "note": "Approved August 5, 2022.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2487,
        "drug_name": "MYFEMBREE (Relugolix)",
        "clinical_trial_id": "NCT03204318",
        "has_trial_insight_page": 0,
        "indication": "Endometriosis-associated pain",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-08-05",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/PFE\/news\/88859",
        "note": "Approved August 5, 2022.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9677,
        "drug_name": "Xofluza (baloxavir marboxil)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Influenza in patients 5 years and older",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-08-11",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/RHHBY\/news\/89717",
        "note": "Approved August 11, 2022.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9682,
        "drug_name": "ENHERTU (fam-trastuzumab deruxtecan-nxki)",
        "clinical_trial_id": "NCT04644237",
        "has_trial_insight_page": 0,
        "indication": "Non-small Cell Lung Cancer (NSCLC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-08-12",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/AZN\/news\/89824",
        "note": "Approved August 12, 2022.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3408,
        "drug_name": "Zynteglo",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "\u03b2-Thalassemia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-08-17",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/BLUE\/news\/90437",
        "note": "Approved August 17, 2022.",
        "company_entity_id": 68,
        "company_ticker": "BLUE",
        "company_name": "bluebird bio Inc.",
        "company_price": "1.3450",
        "company_change": -0.050000000000000044,
        "company_percent_change": -3.24,
        "company_optionable": 1,
        "company_number_of_shares": 109336211,
        "price_change_sparkline": [
            [
                1.02,
                1706677200
            ],
            [
                0.9987,
                1706763600
            ],
            [
                0.9561,
                1706850000
            ],
            [
                0.9052,
                1707109200
            ],
            [
                0.94,
                1707195600
            ],
            [
                0.9357,
                1707282000
            ],
            [
                1.05,
                1707368400
            ],
            [
                1.03,
                1707454800
            ],
            [
                1.09,
                1707714000
            ],
            [
                0.9826,
                1707800400
            ],
            [
                1.025,
                1707886800
            ],
            [
                1.08,
                1707973200
            ],
            [
                1.02,
                1708059600
            ],
            [
                1.1,
                1708405200
            ],
            [
                1.09,
                1708491600
            ],
            [
                1.18,
                1708578000
            ],
            [
                1.25,
                1708664400
            ],
            [
                1.46,
                1708923600
            ],
            [
                1.75,
                1709010000
            ],
            [
                1.68,
                1709096400
            ],
            [
                1.39,
                1709182800
            ],
            [
                1.565,
                1709269200
            ],
            [
                1.53,
                1709528400
            ],
            [
                1.39,
                1709614800
            ],
            [
                1.45,
                1709701200
            ],
            [
                1.45,
                1709787600
            ],
            [
                1.5,
                1709874000
            ],
            [
                1.39,
                1710129600
            ],
            [
                1.345,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4870,
        "drug_name": "AUVELITY",
        "clinical_trial_id": "NCT04019704",
        "has_trial_insight_page": 0,
        "indication": "Major Depressive Disorder",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-08-19",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/AXSM\/news\/90602",
        "note": "FDA Approved on August 19, 2022.",
        "company_entity_id": 61,
        "company_ticker": "AXSM",
        "company_name": "Axsome Therapeutics Inc.",
        "company_price": "69.3900",
        "company_change": -1.54,
        "company_percent_change": -2.17,
        "company_optionable": 1,
        "company_number_of_shares": 47374375,
        "price_change_sparkline": [
            [
                90.03,
                1706677200
            ],
            [
                93.45,
                1706763600
            ],
            [
                92.82,
                1706850000
            ],
            [
                91.5,
                1707109200
            ],
            [
                94.81,
                1707195600
            ],
            [
                94.02,
                1707282000
            ],
            [
                95.68,
                1707368400
            ],
            [
                96.89,
                1707454800
            ],
            [
                97.64,
                1707714000
            ],
            [
                92.26,
                1707800400
            ],
            [
                93.29,
                1707886800
            ],
            [
                93.46,
                1707973200
            ],
            [
                92.81,
                1708059600
            ],
            [
                81.14,
                1708405200
            ],
            [
                82.11,
                1708491600
            ],
            [
                80.47,
                1708578000
            ],
            [
                78.94,
                1708664400
            ],
            [
                82.3,
                1708923600
            ],
            [
                84,
                1709010000
            ],
            [
                82.95,
                1709096400
            ],
            [
                81.38,
                1709182800
            ],
            [
                82.42,
                1709269200
            ],
            [
                78.2,
                1709528400
            ],
            [
                76.62,
                1709614800
            ],
            [
                72.15,
                1709701200
            ],
            [
                72.04,
                1709787600
            ],
            [
                73.92,
                1709874000
            ],
            [
                70.93,
                1710129600
            ],
            [
                69.39,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9862,
        "drug_name": "IMBRUVICA (ibrutinib)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Pediatric Chronic Graft-Versus-Host Disease",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-08-24",
        "link": "https:\/\/www.jnj.com\/u-s-fda-approves-imbruvica-ibrutinib-as-first-and-only-btki-treatment-for-pediatric-patients-with-chronic-graft-versus-host-disease",
        "note": "Approved August 24, 2022.",
        "company_entity_id": 380,
        "company_ticker": "JNJ",
        "company_name": "Johnson & Johnson",
        "company_price": "162.7400",
        "company_change": 1.51,
        "company_percent_change": 0.94,
        "company_optionable": 1,
        "company_number_of_shares": 2408767228,
        "price_change_sparkline": [
            [
                157.701248890579,
                1706677200
            ],
            [
                157.165322682896,
                1706763600
            ],
            [
                155.428524787625,
                1706850000
            ],
            [
                154.6246354761,
                1707109200
            ],
            [
                156.867585900849,
                1707195600
            ],
            [
                156.788189425637,
                1707282000
            ],
            [
                155.220109040193,
                1707368400
            ],
            [
                155.577393178648,
                1707454800
            ],
            [
                156.659170153417,
                1707714000
            ],
            [
                155.289580956004,
                1707800400
            ],
            [
                154.565088119691,
                1707886800
            ],
            [
                156.728642069228,
                1707973200
            ],
            [
                156.55,
                1708059600
            ],
            [
                157.86,
                1708405200
            ],
            [
                158.68,
                1708491600
            ],
            [
                160.45,
                1708578000
            ],
            [
                161.84,
                1708664400
            ],
            [
                160.79,
                1708923600
            ],
            [
                160.98,
                1709010000
            ],
            [
                161.55,
                1709096400
            ],
            [
                161.38,
                1709182800
            ],
            [
                162.12,
                1709269200
            ],
            [
                159.84,
                1709528400
            ],
            [
                159.97,
                1709614800
            ],
            [
                159.34,
                1709701200
            ],
            [
                158.87,
                1709787600
            ],
            [
                159.52,
                1709874000
            ],
            [
                161.23,
                1710129600
            ],
            [
                162.74,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9730,
        "drug_name": "Pemazyre (pemigatinib)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Myeloid\/lymphoid neoplasms (MLNs) with FGFR1 rearrangement",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-08-26",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/INCY\/news\/91278",
        "note": "Approved August 26, 2022.",
        "company_entity_id": 167,
        "company_ticker": "INCY",
        "company_name": "Incyte Corporation",
        "company_price": "59.3300",
        "company_change": -1.46,
        "company_percent_change": -2.4,
        "company_optionable": 1,
        "company_number_of_shares": 224526128,
        "price_change_sparkline": [
            [
                58.77,
                1706677200
            ],
            [
                59.16,
                1706763600
            ],
            [
                58.35,
                1706850000
            ],
            [
                58.06,
                1707109200
            ],
            [
                59.63,
                1707195600
            ],
            [
                57.34,
                1707282000
            ],
            [
                57.36,
                1707368400
            ],
            [
                57.66,
                1707454800
            ],
            [
                57.84,
                1707714000
            ],
            [
                59.34,
                1707800400
            ],
            [
                57.89,
                1707886800
            ],
            [
                58.97,
                1707973200
            ],
            [
                57.96,
                1708059600
            ],
            [
                58.82,
                1708405200
            ],
            [
                60.33,
                1708491600
            ],
            [
                60.91,
                1708578000
            ],
            [
                60.59,
                1708664400
            ],
            [
                60.53,
                1708923600
            ],
            [
                61,
                1709010000
            ],
            [
                59.98,
                1709096400
            ],
            [
                58.36,
                1709182800
            ],
            [
                59.05,
                1709269200
            ],
            [
                59.72,
                1709528400
            ],
            [
                58.9,
                1709614800
            ],
            [
                59.26,
                1709701200
            ],
            [
                59.03,
                1709787600
            ],
            [
                60.02,
                1709874000
            ],
            [
                60.79,
                1710129600
            ],
            [
                59.33,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5081,
        "drug_name": "Libervant (diazepam)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Epileptic seizures",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-08-31",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/AQST\/news\/91698",
        "note": "Tentative approval from FDA on August 31, 2022. The tentative approval was due to to an existing FDA regulatory grant of orphan drug market exclusivity for Valtoco,  a diazepam nasal spray product, Libervant is not yet eligible for marketing in the United States.",
        "company_entity_id": 582,
        "company_ticker": "AQST",
        "company_name": "Aquestive Therapeutics Inc.",
        "company_price": "5.1000",
        "company_change": 0.16,
        "company_percent_change": 3.24,
        "company_optionable": 1,
        "company_number_of_shares": 73301201,
        "price_change_sparkline": [
            [
                2.39,
                1706677200
            ],
            [
                2.67,
                1706763600
            ],
            [
                2.63,
                1706850000
            ],
            [
                2.7,
                1707109200
            ],
            [
                2.79,
                1707195600
            ],
            [
                2.64,
                1707282000
            ],
            [
                2.68,
                1707368400
            ],
            [
                2.75,
                1707454800
            ],
            [
                2.77,
                1707714000
            ],
            [
                2.65,
                1707800400
            ],
            [
                2.68,
                1707886800
            ],
            [
                2.72,
                1707973200
            ],
            [
                2.695,
                1708059600
            ],
            [
                2.65,
                1708405200
            ],
            [
                2.51,
                1708491600
            ],
            [
                2.63,
                1708578000
            ],
            [
                2.57,
                1708664400
            ],
            [
                2.85,
                1708923600
            ],
            [
                3.2,
                1709010000
            ],
            [
                3.65,
                1709096400
            ],
            [
                3.67,
                1709182800
            ],
            [
                4.24,
                1709269200
            ],
            [
                4.18,
                1709528400
            ],
            [
                4.19,
                1709614800
            ],
            [
                5.03,
                1709701200
            ],
            [
                5.68,
                1709787600
            ],
            [
                4.88,
                1709874000
            ],
            [
                4.94,
                1710129600
            ],
            [
                5.1,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9753,
        "drug_name": "ORKAMBI (lumacaftor\/ivacaftor)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Cystic fibrosis (CF) in patients aged 12 to <24 months",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-09-02",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/VRTX\/news\/92121",
        "note": "Approved September 2, 2022.",
        "company_entity_id": 306,
        "company_ticker": "VRTX",
        "company_name": "Vertex Pharmaceuticals Incorporated",
        "company_price": "412.4500",
        "company_change": -2.02,
        "company_percent_change": -0.49,
        "company_optionable": 1,
        "company_number_of_shares": 258307816,
        "price_change_sparkline": [
            [
                433.38,
                1706677200
            ],
            [
                433.87,
                1706763600
            ],
            [
                424.68,
                1706850000
            ],
            [
                428.89,
                1707109200
            ],
            [
                416.13,
                1707195600
            ],
            [
                419.08,
                1707282000
            ],
            [
                423.06,
                1707368400
            ],
            [
                422.91,
                1707454800
            ],
            [
                418.53,
                1707714000
            ],
            [
                416.04,
                1707800400
            ],
            [
                417.88,
                1707886800
            ],
            [
                426.29,
                1707973200
            ],
            [
                422.2,
                1708059600
            ],
            [
                420.64,
                1708405200
            ],
            [
                419.63,
                1708491600
            ],
            [
                426.78,
                1708578000
            ],
            [
                430.11,
                1708664400
            ],
            [
                433.48,
                1708923600
            ],
            [
                430.92,
                1709010000
            ],
            [
                426.97,
                1709096400
            ],
            [
                420.74,
                1709182800
            ],
            [
                432.76,
                1709269200
            ],
            [
                424.03,
                1709528400
            ],
            [
                415.44,
                1709614800
            ],
            [
                411.85,
                1709701200
            ],
            [
                410.54,
                1709787600
            ],
            [
                413.59,
                1709874000
            ],
            [
                414.47,
                1710129600
            ],
            [
                412.45,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3996,
        "drug_name": "DAXXIFY (DaxibotulinumtoxinA-lanm)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Moderate to severe glabellar (frown) lines",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-09-08",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/RVNC\/news\/92882",
        "note": "Approved September 8, 2022.",
        "company_entity_id": 270,
        "company_ticker": "RVNC",
        "company_name": "Revance Therapeutics Inc.",
        "company_price": "6.2850",
        "company_change": 0.03,
        "company_percent_change": 0.4,
        "company_optionable": 1,
        "company_number_of_shares": 88214054,
        "price_change_sparkline": [
            [
                5.03,
                1706677200
            ],
            [
                5.15,
                1706763600
            ],
            [
                5.37,
                1706850000
            ],
            [
                5.1,
                1707109200
            ],
            [
                5.92,
                1707195600
            ],
            [
                5.38,
                1707282000
            ],
            [
                5.42,
                1707368400
            ],
            [
                5.91,
                1707454800
            ],
            [
                5.77,
                1707714000
            ],
            [
                5.22,
                1707800400
            ],
            [
                5.58,
                1707886800
            ],
            [
                5.58,
                1707973200
            ],
            [
                5.56,
                1708059600
            ],
            [
                5.51,
                1708405200
            ],
            [
                5.37,
                1708491600
            ],
            [
                5.31,
                1708578000
            ],
            [
                5.49,
                1708664400
            ],
            [
                5.69,
                1708923600
            ],
            [
                5.7,
                1709010000
            ],
            [
                5.66,
                1709096400
            ],
            [
                7.14,
                1709182800
            ],
            [
                6.98,
                1709269200
            ],
            [
                6.07,
                1709528400
            ],
            [
                6.5,
                1709614800
            ],
            [
                6.34,
                1709701200
            ],
            [
                6.16,
                1709787600
            ],
            [
                6.01,
                1709874000
            ],
            [
                6.26,
                1710129600
            ],
            [
                6.285,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3795,
        "drug_name": "ROLVEDON (eflapegrastim-xnst)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Neutropenia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-09-09",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/SPPI\/news\/93140",
        "note": "Approved September 9, 2022.",
        "company_entity_id": 283,
        "company_ticker": "SPPI",
        "company_name": "Spectrum Pharmaceuticals Inc.",
        "company_price": "1.0300",
        "company_change": 0,
        "company_percent_change": 0,
        "company_optionable": 0,
        "company_number_of_shares": 205261531,
        "statuses": []
    },
    {
        "id": 3795,
        "drug_name": "ROLVEDON (eflapegrastim-xnst)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Neutropenia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-09-09",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/SPPI\/news\/93140",
        "note": "Approved September 9, 2022.",
        "company_entity_id": 622,
        "company_ticker": "ASRT",
        "company_name": "Assertio Holdings Inc.",
        "company_price": "1.0100",
        "company_change": 0.08,
        "company_percent_change": 8.06,
        "company_optionable": 1,
        "company_number_of_shares": 94668523,
        "price_change_sparkline": [
            [
                0.8826,
                1706677200
            ],
            [
                0.8242,
                1706763600
            ],
            [
                0.785,
                1706850000
            ],
            [
                0.7882,
                1707109200
            ],
            [
                0.7975,
                1707195600
            ],
            [
                0.7931,
                1707282000
            ],
            [
                0.793,
                1707368400
            ],
            [
                0.8009,
                1707454800
            ],
            [
                0.8642,
                1707714000
            ],
            [
                0.8014,
                1707800400
            ],
            [
                0.8088,
                1707886800
            ],
            [
                0.8453,
                1707973200
            ],
            [
                0.8545,
                1708059600
            ],
            [
                0.8231,
                1708405200
            ],
            [
                0.7892,
                1708491600
            ],
            [
                0.805,
                1708578000
            ],
            [
                0.82,
                1708664400
            ],
            [
                0.8231,
                1708923600
            ],
            [
                0.8368,
                1709010000
            ],
            [
                0.8472,
                1709096400
            ],
            [
                0.8839,
                1709182800
            ],
            [
                0.8825,
                1709269200
            ],
            [
                0.8825,
                1709528400
            ],
            [
                0.8873,
                1709614800
            ],
            [
                0.89,
                1709701200
            ],
            [
                0.9117,
                1709787600
            ],
            [
                0.9117,
                1709874000
            ],
            [
                0.93,
                1710129600
            ],
            [
                1.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7412,
        "drug_name": "Sotyktu  (Deucravacitinib) - (POETYK PSO-2)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Plaque psoriasis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-09-10",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/BMY\/news\/93163",
        "note": "FDA Approval on September 10, 2022.",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7530,
        "drug_name": "APONVIE (aprepitant)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Postoperative nausea and vomiting (PONV)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-09-16",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/HRTX\/news\/94023",
        "note": "Approved September 16, 2022.",
        "company_entity_id": 157,
        "company_ticker": "HRTX",
        "company_name": "Heron Therapeutics Inc.",
        "company_price": "2.3600",
        "company_change": -0.050000000000000044,
        "company_percent_change": -2.07,
        "company_optionable": 1,
        "company_number_of_shares": 150072640,
        "price_change_sparkline": [
            [
                2.41,
                1706677200
            ],
            [
                2.4,
                1706763600
            ],
            [
                2.39,
                1706850000
            ],
            [
                2.23,
                1707109200
            ],
            [
                2.32,
                1707195600
            ],
            [
                2.26,
                1707282000
            ],
            [
                2.35,
                1707368400
            ],
            [
                2.43,
                1707454800
            ],
            [
                2.63,
                1707714000
            ],
            [
                2.51,
                1707800400
            ],
            [
                2.72,
                1707886800
            ],
            [
                2.88,
                1707973200
            ],
            [
                2.87,
                1708059600
            ],
            [
                2.87,
                1708405200
            ],
            [
                2.75,
                1708491600
            ],
            [
                2.62,
                1708578000
            ],
            [
                2.6,
                1708664400
            ],
            [
                2.6,
                1708923600
            ],
            [
                2.74,
                1709010000
            ],
            [
                2.7,
                1709096400
            ],
            [
                2.66,
                1709182800
            ],
            [
                2.61,
                1709269200
            ],
            [
                2.555,
                1709528400
            ],
            [
                2.56,
                1709614800
            ],
            [
                2.48,
                1709701200
            ],
            [
                2.59,
                1709787600
            ],
            [
                2.6,
                1709874000
            ],
            [
                2.41,
                1710129600
            ],
            [
                2.36,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6964,
        "drug_name": "SKYSONA (elivaldogene autotemcel)",
        "clinical_trial_id": "NCT03852498",
        "has_trial_insight_page": 0,
        "indication": "Cerebral Adrenoleukodystrophy (CALD)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-09-17",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/BLUE\/news\/94064",
        "note": "Approved September 17, 2022.",
        "company_entity_id": 68,
        "company_ticker": "BLUE",
        "company_name": "bluebird bio Inc.",
        "company_price": "1.3450",
        "company_change": -0.050000000000000044,
        "company_percent_change": -3.24,
        "company_optionable": 1,
        "company_number_of_shares": 109336211,
        "price_change_sparkline": [
            [
                1.02,
                1706677200
            ],
            [
                0.9987,
                1706763600
            ],
            [
                0.9561,
                1706850000
            ],
            [
                0.9052,
                1707109200
            ],
            [
                0.94,
                1707195600
            ],
            [
                0.9357,
                1707282000
            ],
            [
                1.05,
                1707368400
            ],
            [
                1.03,
                1707454800
            ],
            [
                1.09,
                1707714000
            ],
            [
                0.9826,
                1707800400
            ],
            [
                1.025,
                1707886800
            ],
            [
                1.08,
                1707973200
            ],
            [
                1.02,
                1708059600
            ],
            [
                1.1,
                1708405200
            ],
            [
                1.09,
                1708491600
            ],
            [
                1.18,
                1708578000
            ],
            [
                1.25,
                1708664400
            ],
            [
                1.46,
                1708923600
            ],
            [
                1.75,
                1709010000
            ],
            [
                1.68,
                1709096400
            ],
            [
                1.39,
                1709182800
            ],
            [
                1.565,
                1709269200
            ],
            [
                1.53,
                1709528400
            ],
            [
                1.39,
                1709614800
            ],
            [
                1.45,
                1709701200
            ],
            [
                1.45,
                1709787600
            ],
            [
                1.5,
                1709874000
            ],
            [
                1.39,
                1710129600
            ],
            [
                1.345,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2411,
        "drug_name": "Pedmark (sodium thiosulfate)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Ototoxicity in non-metastatic, solid tumors",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-09-20",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/FENC\/news\/94429",
        "note": "Approved September 20, 2022.",
        "company_entity_id": 446,
        "company_ticker": "FENC",
        "company_name": "Fennec Pharmaceuticals Inc.",
        "company_price": "9.7200",
        "company_change": 0.25,
        "company_percent_change": 2.64,
        "company_optionable": 1,
        "company_number_of_shares": 26633000,
        "price_change_sparkline": [
            [
                9.99,
                1706677200
            ],
            [
                9.99,
                1706763600
            ],
            [
                10.07,
                1706850000
            ],
            [
                9.79,
                1707109200
            ],
            [
                10.08,
                1707195600
            ],
            [
                10.02,
                1707282000
            ],
            [
                10.13,
                1707368400
            ],
            [
                10.16,
                1707454800
            ],
            [
                10.17,
                1707714000
            ],
            [
                9.4,
                1707800400
            ],
            [
                9.2,
                1707886800
            ],
            [
                9.14,
                1707973200
            ],
            [
                9.01,
                1708059600
            ],
            [
                8.82,
                1708405200
            ],
            [
                8.88,
                1708491600
            ],
            [
                9.03,
                1708578000
            ],
            [
                9,
                1708664400
            ],
            [
                9.14,
                1708923600
            ],
            [
                9.35,
                1709010000
            ],
            [
                9.31,
                1709096400
            ],
            [
                9.47,
                1709182800
            ],
            [
                9.82,
                1709269200
            ],
            [
                9.77,
                1709528400
            ],
            [
                9.57,
                1709614800
            ],
            [
                9.79,
                1709701200
            ],
            [
                9.61,
                1709787600
            ],
            [
                9.66,
                1709874000
            ],
            [
                9.47,
                1710129600
            ],
            [
                9.72,
                1710216000
            ]
        ],
        "statuses": [
            {
                "label": "Orphan Drug Designation (ODD)",
                "abbreviation": "ODD",
                "description": "Orphan Drug Designation (ODD)",
                "description_html": "<p>Orphan Drug Designation (ODD)<\/p>\n"
            }
        ]
    },
    {
        "id": 7579,
        "drug_name": "RETEVMO (Selpercatinib)",
        "clinical_trial_id": "NCT03157128",
        "has_trial_insight_page": 0,
        "indication": "RET Fusion-Positive Solid Tumors",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-09-21",
        "link": "https:\/\/investor.lilly.com\/news-releases\/news-release-details\/fda-approves-lillys-retevmor-selpercatinib-first-and-only-ret",
        "note": "Approved September 21, 2022.",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6266,
        "drug_name": "RETEVMO (Selpercatinib)",
        "clinical_trial_id": "NCT04194944",
        "has_trial_insight_page": 0,
        "indication": "Treatment-na\u00efve RET fusion-positive non-small cell lung cancer (NSCLC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-09-21",
        "link": "https:\/\/www.biopharmcatalyst.com\/company\/LLY\/news\/94536",
        "note": "FDA Approval on September 21, 2022.",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    }
]